KEGG   DRUG: Rilonacept
Entry
D06635                      Drug                                   
Name
Rilonacept (USAN/INN);
Arcalyst (TN)
Product
ARCALYST (Kiniksa Pharmaceuticals (UK))
Formula
C9030H13932N2400O2670S74
Exact mass
201080.7512
Mol weight
201206.5291
Class
Immunological agent
 DG02019  Interleukin inhibitor
Remark
ATC code: L04AC04
Product: D06635<US>
Efficacy
Anti-inflammatory, Antirheumatic
  Disease
Cryopyrin-associated periodic syndromes [DS:H00282]
Comment
Rilonacept is IL-1 receptor fusion protein consisting of the Fc portion of human IgG1 and the human IL-1 receptor.
Target
IL1 [HSA:3552 3553] [KO:K04383 K04519]
  Pathway
hsa04010  MAPK signaling pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04064  NF-kappa B signaling pathway
hsa04620  Toll-like receptor signaling pathway
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AC Interleukin inhibitors
     L04AC04 Rilonacept
      D06635  Rilonacept (USAN/INN) <US>
USP drug classification [BR:br08302]
 Immunological Agents
  Immunological Agents, Other
   Interleukin Blockers
    Rilonacept
     D06635  Rilonacept (USAN/INN)
Drug groups [BR:br08330]
 Immunological agent
  DG02019  Interleukin inhibitor
   D06635  Rilonacept
Drug classes [BR:br08332]
 Immunological agent
  DG02019  Interleukin inhibitor
   D06635  Rilonacept
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Interleukins
    IL1
     D06635  Rilonacept (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D06635
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D06635
Other DBs
CAS: 501081-76-1
PubChem: 47208286
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system